Metoclopramide in Upper Gastrointestinal Bleed

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is

Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed?

Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mercy Health System
• Treatments: Metoclopramide

Criteria

Inclusion Criteria:

• Age 18 and above

• Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside

• Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena

• Plan to undergo EGD within 24 hours since admission or since first symptoms

• Calculated Glasgow-Blatchford score ≥ 2

Exclusion Criteria:

• Failure to obtain informed consent

• Known allergy to metoclopramide

• Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome

• History of TD or dystonic reaction to metoclopramide

• Pheochromocytoma, catecholamine-releasing paragangliomas

• Parkinson's Disease

• Epilepsy

• Pregnancy or lactation

• Previous gastrectomy